Compounds > vidarabine phosphate

vidarabine phosphate and Graft vs Host Disease

vidarabine phosphate has been researched along with Graft vs Host Disease in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (62.50)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afkhami, M; Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Cao, T; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Nakamura, R; O'Donnell, M; Pillai, R; Pullarkat, V; Salhotra, A; Snyder, D; Stein, AS; Yang, D; Yang, L1
Artz, A; De Lima, M; Giralt, S; Kunavakkam, R; Oran, B; Rondon, G; van Besien, K1
Brunstein, CG; Cao, Q; Green, KG; Jacobson, PA; Long-Boyle, JR; McGlave, PB; Miller, JS; Rogosheske, J; Wagner, JE; Weisdorf, DJ1
Deeg, HJ; Furlong, T; Heimfeld, S; McCune, JS; O'Donnell, PV; Storer, B; Wang, J; Woodahl, EL1
Esumi, T; Ichioka, N; Iida, H; Ikehara, S; Inaba, M; Kushida, T1
Abali, H; Aksoy, S; Dinçer, M; Erman, M; Kilickap, S1
Burnett, A; Dasgupta, RK; Davies, J; Jackson, G; Johnson, P; Morgan, GJ; Poynton, C; Richardson, C; Rule, S; Smith, GM; Stars, AC; Tollerfield, SM; Wareham, E; Wilson, K1
Amir, G; Or, R; Polliack, A; Tejman, S; Weiss, L1

Trials

4 trial(s) available for vidarabine phosphate and Graft vs Host Disease

ArticleYear
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Vidarabine Phosphate; Young Adult

2009
High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
    Bone marrow transplantation, 2011, Volume: 46, Issue:1

    Topics: Adult; Aged; Drug Monitoring; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Metabolic Clearance Rate; Middle Aged; Neutrophil Infiltration; Prodrugs; Renal Insufficiency; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Vidarabine Phosphate; Young Adult

2011
A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:1

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Pharmacological; Busulfan; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Recurrence; Survival Rate; Vidarabine Phosphate

2012
Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect.
    Bone marrow transplantation, 2006, Volume: 37, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Infant; Male; Melphalan; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine Phosphate

2006

Other Studies

4 other study(ies) available for vidarabine phosphate and Graft vs Host Disease

ArticleYear
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
    Blood advances, 2019, 01-08, Volume: 3, Issue:1

    Topics: Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Mutation; Primary Myelofibrosis; Prognosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine Phosphate

2019
Successful allogeneic leg transplantation in rats in conjunction with intra-bone marrow injection of donor bone marrow cells.
    Transplantation, 2003, Dec-15, Volume: 76, Issue:11

    Topics: Animals; Bone Marrow Transplantation; Female; Graft Survival; Graft vs Host Disease; Hindlimb; Immunosuppressive Agents; Rats; Rats, Inbred BN; Rats, Inbred F344; Transplantation Conditioning; Transplantation, Homologous; Vidarabine Phosphate; Whole-Body Irradiation

2003
Fludarabine phosphate may be useful in the treatment of graft-versus-host disease.
    Medical hypotheses, 2005, Volume: 64, Issue:6

    Topics: Animals; Antimetabolites; Antineoplastic Agents; CD4 Lymphocyte Count; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukocyte Reduction Procedures; Leukopenia; Mice; Stem Cell Transplantation; T-Lymphocyte Subsets; Vidarabine Phosphate

2005
The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models.
    Bone marrow transplantation, 2000, Volume: 25, Issue:3

    Topics: Animals; Bone Marrow Transplantation; Disease Models, Animal; Graft Survival; Graft vs Host Disease; Histocompatibility; Immunosuppressive Agents; Major Histocompatibility Complex; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Minor Histocompatibility Loci; Survival Rate; Transplantation Chimera; Vidarabine Phosphate; Weight Loss

2000